Cocrystal Pharma (NASDAQ:COCP) Price Target Cut to $12.00

Cocrystal Pharma (NASDAQ:COCP – Get Rating) had its price objective cut by investment analysts at HC Wainwright from $35.00 to $12.00 in a research note issued to investors on Wednesday, The Fly reports. HC Wainwright’s price objective would suggest a potential upside of 438.12% from the stock’s current price.

Cocrystal Pharma Stock Down 2.2 %

Cocrystal Pharma stock opened at $2.23 on Wednesday. Cocrystal Pharma has a 52-week low of $1.74 and a 52-week high of $6.24. The company has a market cap of $22.68 million, a price-to-earnings ratio of -0.46 and a beta of 1.19. The firm’s fifty day moving average is $2.29 and its 200 day moving average is $2.37.

Insider Transactions at Cocrystal Pharma

In related news, Director Phillip Md Et Al Frost purchased 1,015,229 shares of the business’s stock in a transaction dated Tuesday, April 4th. The shares were purchased at an average cost of $1.97 per share, for a total transaction of $2,000,001.13. Following the completion of the acquisition, the director now owns 1,319,838 shares in the company, valued at approximately $2,600,080.86. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 5.50% of the company’s stock.

Institutional Trading of Cocrystal Pharma

An institutional investor recently bought a new position in Cocrystal Pharma stock. Susquehanna International Group LLP acquired a new stake in Cocrystal Pharma, Inc. (NASDAQ:COCP – Get Rating) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 20,728 shares of the company’s stock, valued at approximately $41,000. Susquehanna International Group LLP owned about 0.20% of Cocrystal Pharma as of its most recent SEC filing.

About Cocrystal Pharma

(Get Rating)

Cocrystal Pharma, Inc is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded in 2008 and is headquartered in Bothell, WA.